Received Sep 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | UNK | — | — |
Patient with biopsy-proven C3 glomerulopathy. Who was started on Iptacopan on 06/24/2025. Prior to initiation of Iptacopan, he underwent prophylactic vaccinations according to the protocol and he received Menveo, Bexsero, PCV 20 on 04/15/2025; he also received booster doses 06/16/2025. On 9/2/2025, patient started feeling unwell, complaining of shortness of breath and was found to have respiratory distress, mottling of skin and agitation by EMS on arrival to his house. He was brought to the hospital emergently, eventually he got intubated on arrival in the emergency room due to respiratory distress and agitation. Subsequently, patient was admitted to intensive care unit and was found to have profound DIC with low platelets, severe acute kidney injury requiring initiation of renal replacement therapy, shock that required initiation of pressors then later on he was able to be weaned off pressors, his troponin levels were extremely elevated and his echo showed low ejection fraction. He was started on antibiotics empirically and ID team, Nephrology, Cardiology, Hematology and intensivist were managing his critical situation. Unfortunately, due to extremely low platelets it was unsafe to perform LP. Based on clinical data, it was thought that the most likely cause of his sickness was an infection cased by Neisseria meningitidis likely due to complement inhibition with Iptacopan. ID team recommended continuation of empiric treatment with antibiotics. Patient clinical status deteriorated and family decided to pursue comfort care. Patient was extubated to comfort. Unfortunately patient passed away immediately after extubation.
Iptacopan